原发晚期卵巢癌化疗超过5周期后持续残留病灶行延迟间歇性肿瘤减灭术的作用:一项国际多中心研究
该国际多中心研究分析了2011至2017年间8家妇科肿瘤转诊中心308例新诊断晚期卵巢癌、接受至少5周期新辅助化疗后行延迟间歇性肿瘤减灭术的患者,完全切除率60.1%,完全切除者中位无进展生存期19.5个月、总生存期49.2个月,优于不完全切除者的14.8个月和33.0个月(P=0.001)。作者认为对5周期以上化疗后持续病灶患者,若能达到完全切除,手术可能与有利结局相关。
要点
- 308例接受延迟间歇性肿瘤减灭术,中位术前新辅助化疗6周期(范围5-9),51.3%为IV期。
- 完全切除率60.1%,严重并发症(Clavien-Dindo≥3级)发生率9.7%,术后30天死亡率0.3%。
- 完全切除者中位无进展生存期19.5个月、总生存期49.2个月,不完全切除者为14.8个月和33.0个月(P=0.001)。
核心结论
- 作者认为,对5周期以上化疗后持续病灶患者提供手术,若达到完全切除,可能与有利结局相关。
- 术后有残留病灶的患者可能经历围手术期治疗负担而非从延迟间歇性肿瘤减灭术获益。
研究设计与样本
- 国际多中心研究,分析8家国际妇科肿瘤转诊中心2011至2017年间新诊断晚期卵巢癌、接受至少5周期新辅助化疗后行延迟间歇性肿瘤减灭术的患者数据。
- 共纳入308例患者。
主要发现
- 89.6%为高级别浆液性卵巢癌,中位术前新辅助化疗6周期(范围5-9),6.1%额外接受贝伐珠单抗,51.3%为IV期。
- 中位手术时间210分钟(范围34-561),中位手术复杂评分4分(范围1-16),完全切除率60.1%。
- 中位术后化疗周期数2(范围0-5),严重并发症(Clavien-Dindo≥3级)发生率9.7%,术后30天死亡率0.3%。
- 完全切除者中位无进展生存期19.5个月、总生存期49.2个月,不完全切除者为14.8个月和33.0个月(P=0.001)。
- 与残留病灶>1 cm相比,减灭至小残留(1-10 mm)未观察到生存获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard of care in patients with advanced ovarian cancer (AOC) is upfront surgery followed by chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) is an alternative in selected patients. Most data exist with IDS following 3-4 cycles chemotherapy, however, some patients experience a delay of IDS. So far, the impact of a "delayed" interval debulking surgery (DID) is poorly defined. METHODS: We analyzed data from eight international gynecology-oncology referral centers. Patients were included if they had newly diagnosed AOC and were prone to DID (minimum 5 cycles of NACT) between 2011 and 2017. RESULTS: 308 patients underwent DID. 89.6% had a high-grade serous ovarian cancer. The median number of pre-op NACT was 6 cycles (range 5-9) and 6.1% of patients received additionally bevacizumab. The majority of patients had stage-IV disease (51.3%). Median duration of surgery was 210 min (range 34-561), the median surgical complexity score was 4 (range 1-16). Complete resection was achieved in 60.1%. The median number of post-op chemotherapy cycles was 2 (range 0-5). The rate of severe complications (Clavien-Dindo£3°) was 9.7% and 30 days post-op mortality was 0.3%. The median PFS and OS in patients with complete resection was 19.5 and 49.2 months compared to 14.8 and 33.0 months in patients with incomplete resection (p = 0.001), respectively. We did not observe any survival benefit for patients with cytoreduction to small residuals (1-10 mm) compared to residual disease >1 cm. CONCLUSION: Our data may suggest that offering surgery to patients with persistent disease after 5+ cycles could be associated with favorable outcome if a complete resection is achieved. Patients who had residual disease postoperatively may experience rather peri-operative treatment burden than any benefit from DID.
引用
- Plett H, Filippova OT, Garbi A, et al. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecol Oncol. 2020. PMID: 32919778. doi:10.1016/j.ygyno.2020.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。